Experts Matter. Find Yours.

Starter vape packs to be handed out in hospitals

A new trial from the University of East Anglia will see smokers attending hospital emergency departments given e-cigarette starter packs to help them quit. The initiative comes as a Cochrane Review - the international gold standard for high quality, trusted health information – about vaping is updated today. The review, led by the University of Oxford and involving the UEA team, shows how nicotine electronic cigarettes could increase the number of people who stop smoking compared to nicotine replacement therapy – such as chewing gum and patches – and compared to electronic cigarettes that do not contain nicotine. The new trial will offer stop smoking advice and an e-cigarette ‘starter pack’ to patients attending hospital emergency departments for any reason, to try to encourage and support them to quit smoking – even for those who might not have considered it before. The new trial is funded by the National Institute for Health Research (NIHR) and will be run by the Norwich Clinical Trials Unit at UEA. Prof Caitlin Notley, from UEA’s Norwich Medical School, said; “Many people who smoke want to quit, but find it difficult to succeed in the long term. “Electronic cigarettes mimic the experience of cigarette smoking because they are hand-held and generate a smoke-like vapour when used. They can be an attractive option for helping people switch from smoking, even if they have tried and failed in the past. “We know that they are much less harmful than smoking tobacco, and that they have been shown to help smokers quit. Trial co-lead Dr Ian Pope, also from UEA’s Norwich Medical School and an emergency physician, said: “Emergency Departments in England see over 24 million people each year of whom around a quarter are current smokers. “Attending the Emergency Department offers a valuable opportunity for people to be supported to quit smoking, which will improve their chances of recovery from whatever has brought them to hospital, and also prevent future illness.” The study will run over 30 months across five hospitals in England and Scotland – at the Norfolk and Norwich University Hospital, the Royal London Hospital and Homerton University Hospital in London, Leicester Royal Infirmary and the Royal Infirmary of Edinburgh. Smokers who agree to take part will be randomly assigned to receive either smoking advice during their emergency department wait, an e-cigarette starter pack and referral to local stop smoking services, or just written information about locally available stop smoking services. Both groups of patients will be asked if they are still smoking one, three and six months after they attended hospital. The research team hope to eventually recruit around 1,000 smokers to the trial. Prof Notley said: “We’ll be looking at the number of people who successfully quit smoking across both groups, to see which intervention works best. We’ll also work out how much it would cost to roll the scheme out nationally,” she added. ‘Electronic cigarettes for smoking cessation (Review)’ is published by the Cochrane Library on April 29, 2021.

Thousands of men to trial prostate cancer home testing kit

Thousands of men worldwide are to receive a home test kit for prostate cancer – thanks to pioneering research from the University of East Anglia and the Norfolk and Norwich University Hospital (NNUH). The research team are trialling a new home-testing ‘Prostate Screening Box’ to collect men’s urine samples at-home. The urine samples will be used to analyse the health of the prostate in 2,000 men in the UK, Europe and Canada. This simple urine test is intended to diagnose aggressive prostate cancer and in a pilot study predicted which patients required treatment up to five years earlier than standard clinical methods. Lead researcher Dr Jeremy Clark from the University of East Anglia 'unboxes' the new home testing kit live on Sky News. The Prostate Screening Box has been developed in collaboration with REAL Digital International Limited to create a kit that fits through a standard letterbox. It means that men can provide a urine sample in the comfort of their own home, instead of going into a clinic or having to undergo an uncomfortable rectal examination. The research team hope that it could revolutionise diagnosis of the disease. Lead researcher Dr Jeremy Clark, from UEA’s Norwich Medical School, said: “Prostate cancer is the most common cancer in men in the UK. However it usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime. It is not a simple matter to predict which tumours will become aggressive, making it hard to decide on treatment for many men. “The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination (DRE), an MRI scan or a biopsy. “We have developed the PUR (Prostate Urine Risk) test, which looks at gene expression in urine samples and provides vital information about whether a cancer is aggressive or ‘low risk’. “The Prostate Screening Box part sounds like quite a small innovation, but it means that in future the monitoring of cancer in men could be so much less stressful for them and reduce the number of expensive trips to the hospital. “The prostate lies just below the bladder. It constantly produces secretions which naturally flow into the urethra - the tube through which urine passes from the bladder. The prostatic secretions carry cells and molecules from all over the prostate which are flushed out of the body on urination. We collect these and examine them. It’s a way of sampling the whole prostate in one go. “As the prostate is constantly secreting, the levels of biomarkers in the urethra will build up with time. Collecting from the first wee of the day means that overnight secretions can be collected which makes the analysis more sensitive.” The team have previously trialled the kit with a small group of participants, but in the next phase of the research study are rolling it out to thousands. Men taking part in the trial will receive a home urine-sampling kit and will be asked to provide two urine samples – one to be taken first thing in the morning and the second an hour later. The samples will then be sent back to the lab for analysis. Dr Clark said: “Feedback from early participants showed that the at-home collection was much preferred over sample collection in a hospital. “We hope that using our Prostate Screening Box could in future revolutionise how those on ‘active surveillance’ are monitored for disease progression, with men only having to visit the clinic after a positive urine result. “This is in contrast to the current situation where men are recalled to the clinic every six to 12 months for a range of tests including DRE, PSA tests, painful and expensive biopsies and MRI. We are working to develop the test to help patients in three years’ time. “A negative test could enable men to only be retested every two to three years, relieving stress to the patient and reducing hospital workload,” he added. Robert Mills, Consultant Clinical Director in Urology at NNUH, said: “This simple, non-invasive urine test has the potential to significantly change how we diagnose and manage early prostate cancer for the benefit of patients and health care systems. It may enable us to avoid unnecessary diagnosis of low risk disease as well as managing patients more appropriately with surveillance for those with low risk of progression and early curative treatment for those at high risk of progression.” Paul Villanti, executive director of programs at Movember, said: “The PUR test has great potential to transform the way prostate cancer is managed. Not only can it accurately predict when a man’s disease will become aggressive and require treatment, but it has the added advantage of allowing men to complete it at home. “We are proud to have supported the development of the PUR test from its early stages as part of our Global Action Plan on Biomarkers, through to this trial involving thousands of men across the world. “Through our Global Action Plan on active surveillance, we have been able to identify hundreds of men from the UK, Germany, Italy and Canada who are suitable to take part in this trial. “We hope it will speed up the trial’s progress and get this test included as part of clinical care for men as quickly as possible.” The research has been funded by a Movember and Prostate Cancer UK Innovation award, the Masonic Charitable Foundation, the Bob Champion Cancer Trust, the King family, the Andy Ripley Memorial Fund, the Hargrave Foundation, Norfolk Freemasons and the Tesco Centenary Grant.

Expert available to discuss Facebook Oversight Board's decision on Trump's account

Reporters: Girish Mallapragada, a social media marketing expert at the Indiana University Kelley School of Business, is available Wednesday (May 5) to discuss the Facebook Oversight Board's decision to uphold Facebook's ban on former President Donald Trump. In advance of the announcement, Mallapragada, an associate professor of marketing and Weimer Faculty Fellow, said he questioned whether the board’s decision will have much of an impact on Trump’s outreach to his followers. He noted that Trump’s rise in popularity primarly came through his use of another social media platform, Twitter, and not as much through Facebook. “He was more adept at short form communication than long contextual messages. Twitter is ideal for the former, Facebook for the latter,” Mallapragada said. “Twitter is closest online to a live large audience, where he thrives.” “If Facebook allows him to comeback, it might make people unhappy and others happy, but I don’t think it would be impactful to make a big difference.” George Vlahakis, associate director of communications and media relations at Kelley, can help arrange for interviews with Mallapragada, and can be reached at vlahakis@iu.edu.

STORY: CAA is Canada’s most trusted brand for the second year running.

​The Canadian Automobile Association (CAA) has been named the most trusted brand in Canada for the second year in a row in the annual Gustavson Brand Trust Index, released today. Since being named in the Index five years ago, CAA has been one of the top two trusted brands, beating out several hundred other prominent international and Canadian brands. CAA has received the top trusted spot, four years consecutively in the insurance category. In addition, CAA leads the pack this year on the following trust attributes: good customer treatment and honest communications. Conducted by the Peter B. Gustavson School of Business at the University of Victoria, the sixth annual Gustavson Brand Trust Index asked more than 7,800 consumers to score 342 prominent Canadian companies and brands, across 27 industry sectors, on a range of brand value measures.​ Consumers are asked to assess their perception of the reliability, consistency, honesty, societal responsibility and integrity of the brands surveyed. CAA Clubs are active in communities across Canada. At the start of the pandemic, the clubs quickly pivoted to offer community services, including deliveries of food and medical supplies, free roadside assistance to medical workers, and calls to housebound seniors. Full report 2021 Gustavson Brand Trust Index

Assessing Biden's "Green Infrastructure" Plan From a Climate Perspective

In a virtual climate summit attended by leaders from all over the globe, President Joseph Biden announced plans for the United States to cut carbon emissions by as much as 52% by the year 2030. This commitment was outlined in what the Biden administration is calling a "green infrastructure" bill, one that has echoes of the Obama-era Green New Deal.  Samantha Chapman, PhD, a biology professor at Villanova University and co-director of the Center for Biodiversity and Ecosystem Stewardship, recently broke down the pros and cons of the bill with KYW Newsradio's Matt Leon. According to Dr. Chapman, the bill addresses what she identifies as the two major strategies for mitigating the negative effects of our warming planet: "preventing more climate change and adapting to climate change." Dr. Chapman considers that the strength of the bill lies in what she and Matt Leon refer to as "base hits" rather than the "home run" structure of the Green New Deal, meaning that Biden's plan relies on smaller, easily achievable goals—like incentivizing a switch to a more sustainable type of cement for building bridges—rather than sweeping reform in an effort to get the bill passed. Dr. Chapman calls the improvement of the power grid, which would support the manufacturing of electric cars and ease our nation's reliance on fossil fuels, "one of the biggest things in the bill." The professor also notes that she is hopeful about the installation of broadband in remote areas allowing for wider internet access and investment in energy-efficient affordable housing and job training to support communities that rely on the fossil fuel industries. "You can't just shut these people's livelihoods down and say 'okay, good luck' or just give them a payout. People want to have jobs that fulfill them," says Dr. Chapman. This direction, focusing on infrastructure with climate and equity at the center of the conversation, is in line with the Biden campaign's slogan to "build back better." Dr. Chapman points out that this bill creates an opportunity to focus on the word "better" by reevaluating the definition of infrastructure itself. "What is infrastructure?" she asks. "Is clean air infrastructure? Is clean water infrastructure? We know that natural infrastructures [feedback systems like our waterways and forests]—and we still have a lot of them in the U.S., thankfully—give us a buffer against climate change." As a climate scientist specializing in coastal ecosystems, Dr. Chapman told Leon she hopes to see an emphasis on these types of natural infrastructures. "I think that salt marshes and mangroves are really important in buffering our coast against big storms, so I want to see explicitly that we are going restore these places. It would be good for biodiversity; it would be good for people hanging out and kayaking; and it would help us protect against these big storms that are coming whether or not we cap our emissions. I think I would like to see more of these green barriers along our coast rather than big seawalls, and I haven't seen that exactly yet, but again the fine print's not there," she points out. "The bill's not done." Finally, Dr. Chapman spoke to how this infrastructure bill could have an impact on the future of the country if it is passed and observed. "I think there's still work to do on things like forests and biodiversity; there's always more work to do. I think it would be a massive step in the right direction. And then we'd have to go to the rest of the world and start doing some work there."

Autonomous cars expert: Dr Siddartha Khastgir

For stories on autonomous vehicles, Dr Siddartha Khastgir from WMG at the University of Warwick is one of the leading experts in the UK, and is available for comment.  His recent notable research includes developing the world’s largest public database for testing driverless cars: If you would like to interview him, contact press@warwick.ac.uk or L.Walton.1@warwick.ac.uk

Did the Johnson & Johnson pause impact COVID-19 vaccine hesitation in Black and Hispanic communities?

The Food and Drug Administration and the Centers for Disease Control and Prevention recently lifted the pause on the Johnson & Johnson COVID-19 vaccine. The agencies had shelved the vaccine after it was linked to cases of an extremely rare blood clotting disorder. Public health officials are now concerned that as news gets out about the potential side effects of the Johnson & Johnson vaccine, some members of the Black and Hispanic communities may opt out of what could be a life-saving act. “To the Black and Hispanic communities, there has been a long history of untrustworthy behavior by health care systems, and the current issue with Johnson & Johnson may have worsened some hesitancy,” said Dr. Justin X. Moore, an epidemiologist in the Department of Population Health Sciences at the Medical College of Georgia. “To overcome this barrier, companies must continue being open about side effects of the vaccine, and health care workers must be empathetic and listen to their patients’ concerns.” Vaccine safety and the importance of everyone being vaccinated is crucial as America looks to get to the light at the end of this pandemic. If you are a journalist covering COVID-19 and the issues surrounding vaccine hesitancy, then let our experts help. Dr. Justin Moore is an expert in spatial epidemiology and an associate professor at the Institute of Public and Preventive Health at Augusta University. He is available to speak with media regarding this topic – simply click on his name to arrange an interview.

Faculty-student collaborations showcase professional growth, creativity at Georgia Southern's Spring 2021 Honors Research Symposium April 26-30

Ambitious student research collaborations with faculty members often lead to much more than good grades. The mentorships encourage professional growth, confidence and creativity, even in the midst of a pandemic. Georgia Southern University’s Spring 2021 Honors Research Symposium, which is being held virtually April 26 through April 30, will showcase faculty-student partnerships through a broad range of scholarly and creative research projects produced by more than 100 honors students across multiple disciplines on the Statesboro and Armstrong campuses. A few of the presenters include: Chelsea Riley, a triple major in international studies, political science and Spanish, worked with political science and international studies professor Srobana Bhattacharya, Ph.D., on her thesis, “The Culture Gap: The Role of Culture in Successful Refugee Settlement.” History and English major Jacey Thomas, mentored by associate professor of history Alan Downs, Ph.D., will present, “Irish Rock Music amid a Time of Troubles: Thin Lizzy and U2 as a Bridge During a Time of Division.” Biology major Susan Ihejirika’s presentation, “A Forward Genetic Screen to Identify Human Genes of Interest and Their Roles in Ovarian Cancer,” was guided by biology assistant professor Dongyu Jia, Ph.D. The Honors College, as the university-wide center for excellence in undergraduate education, plays a crucial role with undergraduate research at Georgia Southern. Since the beginning of the College, students have been required to complete honors theses or capstone projects. The faculty-mentored projects have spanned traditional research models, applied research and creative activities in all academic colleges and majors. “Through faculty-mentored research and scholarly activities, honors students create new knowledge and the Honors Research Symposium is the venue where we share it with the broader scholarly community,” said Honors College Dean Steven Engel, Ph.D. “ I am proud of the fact that they have been able to complete these projects despite the challenges of the past year.” Presentations will be posted on YouTube and the comments section will be open for audience engagement with presenters. If you're a journalist looking to learn more about this year’s Honors Research Symposium — simply reach out to Georgia Southern Director of Communications Jennifer Wise at jwise@georgiasouthern.edu.

New prostate cancer urine test shows how aggressive disease is and could reduce invasive biopsies

Researchers from the University of East Anglia have developed a new urine test for prostate cancer which also shows how aggressive the disease is. A new study shows how an experimental new test called ‘ExoGrail’ has the potential to revolutionise how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy. The research team say their new test could reduce the number of unnecessary prostate cancer biopsies by 35 per cent. Prostate cancer is the most common cancer in men in the UK. It usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime. The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination (DRE), an MRI scan or an invasive biopsy. However, doctors struggle to predict which tumours will become aggressive, making it hard to decide on treatment for many men. Lead researcher Dr Dan Brewer, from UEA’s Norwich Medical School, said: “While prostate cancer is responsible for a large proportion of all male cancer deaths, it is more commonly a disease men die with rather than from. “Therefore, there is a desperate need for improvements in diagnosing and predicting outcomes for prostate cancer patients to minimise over-diagnosis and overtreatment whilst appropriately treating men with aggressive disease, especially if this can be done without taking an invasive biopsy. “Invasive biopsies come at considerable economic, psychological and societal cost to patients and healthcare systems alike.” The research team developed the new ExoGrail urine test by combining two biomarker sources - measurements of a protein-marker called EN2 and the levels of gene expression of 10 genes related to prostate cancer risk. It builds on previously developed tests called PUR and ExoMeth. They tested it using urine samples from 207 patients who had been undergone a biopsy for prostate cancer at the Norfolk and Norwich University Hospital (NNUH). When the urine results were compared to biopsy results, the study showed that the test had successfully shown which patients had prostate cancer and which did not. The ExoGrail test also provided risk scores for patients and highlighted those for which an invasive biopsy would have been beneficial. The findings show that using information from multiple, non-invasive biomarker sources has the potential to greatly improve how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy. Dr Brewer said: “Our new urine test not only shows whether a patient has prostate cancer, but it importantly shows how aggressive the disease is. This allows patients and doctors to select the correct treatment. And it has the potential to reduce the number of unnecessary biopsies by 35 per cent.” The research team was led by Dr Shea Connell, Prof Colin Cooper, Dr Daniel Brewer and Dr Jeremy Clark, all from UEA’s Norwich Medical School, in collaboration with the Norfolk and Norwich University Hospital, the University of Surrey, the University of Bradford, The Earlham Institute, and The Movember GAP1 Urine Biomarker Consortium. The urine biomarker research was funded by the Movember GAP1 Urine Biomarker project, Prostate Cancer UK, The Masonic Charitable Foundation, The Bob Champion Cancer Trust, the King family, The Andy Ripley Memorial Fund, the Hargrave Foundation, Norfolk Freemasons and the Tesco Centenary Grant. Paul Villanti, executive director of programmes at Movember, said: “We are proud to have supported the development of the ExoGrail urine test as part of our Global Action Plan Urine Biomarker project. “Having non-invasive tests which can accurately show how aggressive a man’s prostate cancer is not only reduces the number of men having to undergo painful biopsies, but also ensures that the right course of treatment for the patient is selected more quickly.” ‘Integration of Urinary EN2 Protein & Cell-Free RNA Data in the Development of a Multivariable Risk Model for the Detection of Prostate Cancer Prior to Biopsy’ is published in the journal Cancers on Tuesday, April 27, 2021.

Novel coronavirus discovered in British bats

A coronavirus related to the virus that causes Covid-19 in humans has been found in UK horseshoe bats – according to new collaborative research from the University of East Anglia, ZSL (Zoological Society of London), and Public Health England (PHE). However, there is no evidence that this novel virus has been transmitted to humans, or that it could in future, unless it mutates. UEA researchers collected faecal samples from more than 50 lesser horseshoe bats in Somerset, Gloucestershire and Wales and sent them for viral analysis at Public Health England. Genome sequencing found a novel coronavirus in one of the bat samples, which the team have named ‘RhGB01’. Due to the rapid response nature of this research, it has not yet been peer reviewed. It is the first time that a sarbecovirus (SARS-related coronavirus) has been found in a lesser horseshoe bat and the first to be discovered in the UK. The research team say that these bats will almost certainly have harboured the virus for a very long time. And it has been found now, because this is the first time that they have been tested. Importantly, this novel virus is unlikely to pose a direct risk to humans, unless it mutates. A mutation could happen if a human infected with Covid-19 passes it to an infected bat, so anyone coming into contact with bats or their droppings, for example those engaged in caving or bat protection, should wear appropriate PPE. Prof Diana Bell, an expert in emerging zoonotic diseases from UEA’s School of Biological Sciences, said: “Horseshoe bats are found across Europe, Africa, Asia and Australia and the bats we tested lie at the western extreme of their range. “Similar viruses have been found in other horseshoe bat species in China, South East Asia and Eastern Europe. “Our research extends both the geographic and species ranges of these types of viruses and suggests their more widespread presence across more than 90 species of horseshoe bats. “These bats will almost certainly have harboured this virus for a very long time – probably many thousands of years. We didn’t know about it before because this is the first time that such tests have been carried out in UK bats. “We already know that there are different coronaviruses in many other mammal species too,” she said. “This is a case of ‘seek and you will find’. “Research into the origins of SARS-CoV-2, the virus that causes Covid-19 in humans, has focussed on horseshoe bats - but there are some 1,400 other bat species and they comprise 20 per cent of known mammals. “Our findings highlight the need for robust genotype testing for these types of viruses in bat populations around the world. And it raises an important question about what other animals carry these types of viruses.” Prof Andrew Cunningham, from the Zoological Society of London, said: “Our findings highlight that the natural distribution of sarbecoviruses and opportunities for recombination through intermediate host co-infection have been underestimated. “This UK virus is not a threat to humans because the receptor binding domain (RBD) – the part of the virus that attaches to host cells to infect them - is not compatible with being able to infect human cells. “But the problem is that any bat harbouring a SARS-like coronavirus can act as a melting pot for virus mutation. So if a bat with the RhGB01 infection we found were to become infected with SARS-CoV-2, there is a risk that these viruses would hybridise and a new virus emerge with the RBD of SARS-CoV-2, and so be able to infect people. “Preventing transmission of SARS-CoV-2 from humans to bats, and hence reducing opportunities for virus mutation, is critical with the current global mass vaccination campaign against this virus.” Prof Bell added: “The main risks would be for example a bat rehabilitator looking after a rescued animal and infecting it with SARS-CoV2 - which would provide an opportunity for genetic recombination if it is already carrying another sarbecovirus. “Anyone coming into contact with bats or their droppings, such as bat rescuers or cavers, should wear appropriate PPE – in order to reduce the risk of a mutation occurring. “We need to apply stringent regulations globally for anyone handling bats and other wild animals,” she added. The new virus falls within the subgroup of coronaviruses called sarbecoviruses which contains both SARS-CoV-2 (responsible for the current pandemic) and SARS-CoV (responsible for the initial 2003 SARS outbreak in humans). Further analysis compared the virus with those found in other horseshoe bat species in China, South East Asia and Europe and showed that its closest relative was discovered in a Blasius’s bat from Bulgaria in 2008. Ivana’s story The UK discovery was made by undergraduate ecology student Ivana Murphy, from UEA’s School of Biological Sciences, who collected bat droppings as part of her final year research dissertation. Jack Crook conducted the genetic analyses in partnership with other researchers at PHE. A total of 53 bats were captured, and their faeces collected in sterile bags. The research was conducted under strict Health and Safety protocols. Full PPE was worn and Ivana was regularly tested for Covid-19 to avoid any chance of cross contamination. The bats were released immediately after their droppings had been collected. Ivana said: “I am very fortunate to be surrounded by so many experts in their fields, which has allowed me access to resources that many undergraduates wouldn’t have. I feel extremely lucky to have been able to conduct such an advanced study.” “We weren’t shocked by the results, but I am extremely eager to carry out further research. “I chose to study ecology at UEA as I have a passion for trying to protect and conserve nature. I wanted a better understanding of the global situation and so chose UEA to study ecology and conservation. “The plan after graduation is to do an extended study of viruses in UK bats, very similar to the one I carried out as an undergraduate. There is still a lot more to understand and I am extremely excited to see what else we can find out.” But she says that she doesn’t want her research to turn people against bats. “More than anything, I’m worried that people may suddenly start fearing and persecuting bats, which is the last thing I would want and would be unnecessary. As like all wildlife, if left alone they do not pose any threat.” ‘Metagenomic identification of a new sarbecovirus from horseshoe bats in Europe’ is published on the Research Square pre-print server. Read the full story, including a Q&A with all you need to know.